Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis

Inclusion Criteria:

• First episode psychosis (onset within the last 2 years) or attenuated psychosissyndrome (APS), stabilized with treatment for at least 8 weeks prior to initiatingthe trial consistent with the FDA-NIMH-MATRICS guidelines for clinical trial designfor clinical enhancing drugs:

• Clinically stable and in a nonacute phase of their illness for at least 2 months,First episode psychosis participants will have been maintained on currentantipsychotic for at least 6 weeks, with no change in antipsychotic dose for theprevious 4 weeks while APS participants will be on the same treatment regimen (psychosocial or pharmacologic) for 4 weeks,

• Exhibit no more than moderate levels of positive symptoms (defined by ratings of ≤

4. on PANSS items P1 (delusions), P2 (conceptual disorganization), P3 (hallucinatorybehavior), P5 (grandiosity), P6 (suspiciousness), and G8 (unusual thought content),

• No more than a minimal level of depressive symptoms as assessed by the CalgaryDepression Scale for Schizophrenia (CDSS)

• Acceptable diagnoses will include APS, Psychosis NOS, Schizophreniform,Schizophrenia, and Schizoaffective per the Structured Clinical Interview for DSM-V.

Exclusion Criteria:

• Concomitant medical or neurological illness;

• Significant head injury;

• Impaired intellectual functioning IQ<80; however those with an IQ i the 75-79 rangewill be include if WRAT reading > 85 suggesting higher premorbid IQ.

• High suicidal risk assessed by the The Columbia-Suicide Severity Rating Scale (C-SSRS)42

• Pregnant women and those who do not agree to avoid becoming pregnant

• Patients requiring treatment with Azelastine, Azelastine; Fluticasone, Dronabinol,Valproic Acid, or Divalproex Sodium